| Identification | Back Directory | [Name]
AC 010220 (dihydrochloride) | [CAS]
1132827-21-4 | [Synonyms]
AC-220;AC220
Quizartinib HCl
AC 220 dihydrochloride
Quizartinib HCl (AC-220
Quizartinib hydrochloride
AC 010220 (dihydrochloride)
Quizartinib dihydrochloride
1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea:dihydrochloride | [Molecular Formula]
C29H33ClN6O4S | [MOL File]
1132827-21-4.mol | [Molecular Weight]
597.13 |
| Hazard Information | Back Directory | [Uses]
Quizartinib dihydrochloride (AC220 dihydrochloride) is the dihydrochloride salt form of Quizartinib (HY-13001). Quizartinib dihydrochloride is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a Kd of 1.6 nM. Quizartinib dihydrochloride inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC50s of 4.2 and 1.1 nM, respectively. Quizartinib dihydrochloride can be linked to the VHL ligand via an optimized linker to form a PROTAC FLT3 degrader. Quizartinib dihydrochloride induces apoptosis[1][2][3]. | [References]
[1] Zarrinkar PP, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood, 2009, 114(14), 2984-2992. DOI:10.1182/blood-2009-05-222034
[2] Puissant A, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014 Feb 10;25(2):226-42. DOI:10.1016/j.ccr.2014.01.022
[3] Sun X, et al. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther. 2019 Dec 24;4:64. DOI:10.1038/s41392-019-0101-6 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Wuhan Topule
|
| Tel: |
+86-02787215551 +86-19945035818 |
| Website: |
http://www.topule.com/ |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|